196 related articles for article (PubMed ID: 9059563)
1. Effects of prolonged bisphosphonate therapy and its discontinuation on bone mineral density in post-menopausal osteoporosis.
Orr-Walker B; Wattie DJ; Evans MC; Reid IR
Clin Endocrinol (Oxf); 1997 Jan; 46(1):87-92. PubMed ID: 9059563
[TBL] [Abstract][Full Text] [Related]
2. Site-dependent bone mineral density response to oral pamidronate and calcium in postmenopausal osteoporosis: a preliminary report.
Barreira JC; Messina OD; Maldonado-Cocco JA; Roldan EJ
Clin Rheumatol; 1997 Jun; 16(4):346-52. PubMed ID: 9259247
[TBL] [Abstract][Full Text] [Related]
3. Differential action of pamidronate on trabecular and cortical bone in women with involutional osteoporosis.
Fromm GA; Vega E; Plantalech L; Galich AM; Mautalen CA
Osteoporos Int; 1991 Jun; 1(3):129-33. PubMed ID: 1790400
[TBL] [Abstract][Full Text] [Related]
4. Role of oral pamidronate in preventing bone loss in postmenopausal women.
Lees B; Garland SW; Walton C; Ross D; Whitehead MI; Stevenson JC
Osteoporos Int; 1996; 6(6):480-5. PubMed ID: 9116394
[TBL] [Abstract][Full Text] [Related]
5. Continuous therapy with pamidronate, a potent bisphosphonate, in postmenopausal osteoporosis.
Reid IR; Wattie DJ; Evans MC; Gamble GD; Stapleton JP; Cornish J
J Clin Endocrinol Metab; 1994 Dec; 79(6):1595-9. PubMed ID: 7989461
[TBL] [Abstract][Full Text] [Related]
6. Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis.
Thiébaud D; Burckhardt P; Kriegbaum H; Huss H; Mulder H; Juttmann JR; Schöter KH
Am J Med; 1997 Oct; 103(4):298-307. PubMed ID: 9382122
[TBL] [Abstract][Full Text] [Related]
7. The impact of vitamin D status on changes in bone mineral density during treatment with bisphosphonates and after discontinuation following long-term use in post-menopausal osteoporosis.
Deane A; Constancio L; Fogelman I; Hampson G
BMC Musculoskelet Disord; 2007 Jan; 8():3. PubMed ID: 17214897
[TBL] [Abstract][Full Text] [Related]
8. Mineral density gain in vertebrae of osteoporotic women on oral pamidronate reverts a year after treatment discontinuance.
Zanchetta JR; Plotkin H; Roldán EJ
Calcif Tissue Int; 1996 Jul; 59(1):70-2. PubMed ID: 8661988
[TBL] [Abstract][Full Text] [Related]
9. Continuous combined oestrogen/progestin therapy is well tolerated and increases bone density at the hip and spine in post-menopausal osteoporosis.
Grey AB; Cundy TF; Reid IR
Clin Endocrinol (Oxf); 1994 May; 40(5):671-7. PubMed ID: 8013147
[TBL] [Abstract][Full Text] [Related]
10. Treatment of post-menopausal osteoporosis with a combination of growth hormone and pamidronate: a placebo controlled trial.
Erdtsieck RJ; Pols HA; Valk NK; van Ouwerkerk BM; Lamberts SW; Mulder P; Birkenhäger JC
Clin Endocrinol (Oxf); 1995 Nov; 43(5):557-65. PubMed ID: 8548940
[TBL] [Abstract][Full Text] [Related]
11. Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis.
McClung MR; Wasnich RD; Recker R; Cauley JA; Chesnut CH; Ensrud KE; Burdeska A; Mills T;
J Bone Miner Res; 2004 Jan; 19(1):11-8. PubMed ID: 14753731
[TBL] [Abstract][Full Text] [Related]
12. A phase 2 study of MK-5442, a calcium-sensing receptor antagonist, in postmenopausal women with osteoporosis after long-term use of oral bisphosphonates.
Cosman F; Gilchrist N; McClung M; Foldes J; de Villiers T; Santora A; Leung A; Samanta S; Heyden N; McGinnis JP; Rosenberg E; Denker AE
Osteoporos Int; 2016 Jan; 27(1):377-86. PubMed ID: 26556736
[TBL] [Abstract][Full Text] [Related]
13. Better late than never? Experience with intravenous pamidronate treatment in patients with low bone mass or fractures following cardiac or liver transplantation.
Dodidou P; Bruckner T; Hosch S; Haass M; Klar E; Sauer P; Ziegler R; Leidig-Bruckner G
Osteoporos Int; 2003 Jan; 14(1):82-9. PubMed ID: 12577189
[TBL] [Abstract][Full Text] [Related]
14. Changes in bone mineral density after kidney transplantation: 2-year assessment of a French cohort.
Segaud N; Legroux I; Hazzan M; Noel C; Cortet B
Osteoporos Int; 2018 May; 29(5):1165-1175. PubMed ID: 29500526
[TBL] [Abstract][Full Text] [Related]
15. [Alendronate in postmenopausal women with osteopenia and osteoporosis: effects on bone mineral density during treatment and after withdrawal].
Jiang Y; Li M; Xia W; Xing X; Yu W; Tian J; Meng X; Zhou X
Zhonghua Yi Xue Za Zhi; 2002 Sep; 82(18):1254-6. PubMed ID: 12425805
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study.
Emkey R; Delmas PD; Bolognese M; Borges JL; Cosman F; Ragi-Eis S; Recknor C; Zerbini CA; Neate C; Sedarati F; Epstein S
Clin Ther; 2009 Apr; 31(4):751-61. PubMed ID: 19446148
[TBL] [Abstract][Full Text] [Related]
17. Long-term change in the bone mineral density of adults with adult onset growth hormone (GH) deficiency in response to short or long-term GH replacement therapy.
Rahim A; Holmes SJ; Adams JE; Shalet SM
Clin Endocrinol (Oxf); 1998 Apr; 48(4):463-9. PubMed ID: 9640413
[TBL] [Abstract][Full Text] [Related]
18. Determinants of change in bone mineral density and fracture risk during bisphosphonate holiday.
Xu LH; Adams-Huet B; Poindexter JR; Maalouf NM
Osteoporos Int; 2016 May; 27(5):1701-8. PubMed ID: 26642963
[TBL] [Abstract][Full Text] [Related]
19. Intravenous pamidronate as treatment for osteoporosis after heart transplantation: a prospective study.
Krieg MA; Seydoux C; Sandini L; Goy JJ; Berguer DG; Thiébaud D; Burckhardt P
Osteoporos Int; 2001; 12(2):112-6. PubMed ID: 11303710
[TBL] [Abstract][Full Text] [Related]
20. Association between bone mineral densities and serum lipid profiles of pre- and post-menopausal rural women in South Korea.
Cui LH; Shin MH; Chung EK; Lee YH; Kweon SS; Park KS; Choi JS
Osteoporos Int; 2005 Dec; 16(12):1975-81. PubMed ID: 16167087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
